Last reviewed · How we verify
Palonosetron with Dexamethasone
At a glance
| Generic name | Palonosetron with Dexamethasone |
|---|---|
| Also known as | Palonosetron, Aloxi, Dexamethasone, Decadron |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients (NA)
- AKY15-HK-301_NEPA Study (PHASE2)
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients (PHASE4)
- HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents (PHASE3)
- Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palonosetron with Dexamethasone CI brief — competitive landscape report
- Palonosetron with Dexamethasone updates RSS · CI watch RSS
- NYU Langone Health portfolio CI